Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

Author:

Guttman-Yassky Emma¹,Blauvelt Andrew²,Eichenfield Lawrence F.³⁴⁵,Paller Amy S.⁶,Armstrong April W.⁷,Drew Janice⁸,Gopalan Ramanan⁸,Simpson Eric L.⁹

Affiliation:

1. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

2. Principal Investigator and President, Oregon Medical Research Center, Portland

3. Department of Dermatology, University of California, San Diego

4. Department of Pediatrics, University of California, San Diego

5. Pediatric and Adolescent Dermatology, Rady Children’s Hospital, San Diego, California

6. Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

7. Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles

8. Dermira, Inc, Menlo Park, California

9. Department of Dermatology, Oregon Health & Science University, Portland

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

Reference60 articles.

1. Biological therapies for atopic dermatitis: an update.;Deleanu;Exp Ther Med,2019

2. The challenge of managing atopic dermatitis in the United States.;Feldman;Am Health Drug Benefits,2019

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献